Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.420
-0.010 (-0.41%)
At close: Dec 5, 2025, 4:00 PM EST
2.440
+0.020 (0.83%)
After-hours: Dec 5, 2025, 7:34 PM EST
Editas Medicine Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Editas Medicine stock ranges from a low of $3.00 to a high of $6.00. The average analyst price target of $4.13 forecasts a 70.66% increase in the stock price over the next year.
Price Target: $4.13 (+70.66%)
Analyst Consensus: Buy
* Price targets were last updated on Sep 5, 2025.
Analyst Ratings
The average analyst rating for Editas Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 6 | 5 | 5 | 5 | 5 | 5 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 12 | 12 | 12 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +106.61% | Sep 5, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $3 → $4 | Hold | Maintains | $3 → $4 | +65.29% | Sep 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $3 → $5 | Strong Buy | Maintains | $3 → $5 | +106.61% | Aug 15, 2025 |
| Baird | Baird | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +147.93% | Aug 13, 2025 |
| Baird | Baird | Buy Maintains $8 → $4 | Buy | Maintains | $8 → $4 | +65.29% | May 13, 2025 |
Financial Forecast
Revenue This Year
20.42M
from 32.31M
Decreased by -36.82%
Revenue Next Year
13.65M
from 20.42M
Decreased by -33.14%
EPS This Year
-2.06
from -2.88
EPS Next Year
-1.11
from -2.06
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 26.3M | 31.5M | ||||
| Avg | 20.4M | 13.7M | ||||
| Low | 16.0M | 2.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -18.8% | 54.3% | ||||
| Avg | -36.8% | -33.1% | ||||
| Low | -50.6% | -90.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.95 | -0.65 | ||||
| Avg | -2.06 | -1.11 | ||||
| Low | -2.09 | -1.55 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.